Journal article
2800O A randomised trial of continuing or de-escalating bone modifying agents (BMA) after more than 2 years of treatment in patients with bone metastases from breast or castration-resistant prostate cancer: REaCT-Hold BMA
Authors
Ng TL; Sienkiewicz M; Pond GR; Rushton M; Hilton JF; Srikanthan A; Mcgee S; Awan AA; Savard M-F; Fernandes R
Journal
Annals of Oncology, Vol. 36, , pp. s1488–s1489
Publisher
Elsevier
Publication Date
September 1, 2025
DOI
10.1016/j.annonc.2025.08.3412
ISSN
0923-7534